Welcome to our dedicated page for MyMD Pharmaceuticals news (Ticker: MYMD), a resource for investors and traders seeking the latest updates and insights on MyMD Pharmaceuticals stock.
MyMD Pharmaceuticals, Inc. (DE) (NASDAQ: MYMD) is a clinical-stage biopharmaceutical company that focuses on extending healthy lifespan through the development of innovative therapeutic platforms. The company is committed to addressing serious autoimmune and inflammatory diseases as well as age-related conditions.
Core Therapeutic Platforms:
- MyMD-1: This is a small molecule drug platform that aims to regulate the immunometabolic system by controlling tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines. MyMD-1 is being developed to treat autoimmune diseases such as multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Additionally, it targets age-related illnesses, including frailty and sarcopenia. The drug’s oral administration is a significant advantage over existing TNF-α inhibitors, which require injectable forms.
- Supera-CBD: This drug platform is based on a novel synthetic derivative of cannabidiol (CBD) that targets key receptors, including CB2 and opioid receptors, and inhibits monoamine oxidase. Supera-CBD is designed to cater to the rapidly expanding CBD market, addressing conditions such as epilepsy, pain, and anxiety/depression.
Recent Achievements and Current Projects:
MyMD Pharmaceuticals has made significant strides in its clinical trials, particularly with MyMD-1. In a recently completed phase 2 clinical trial, MyMD-1 successfully met its primary endpoints by reducing biomarkers common in chronic inflammatory diseases, such as TNF-α, IL-6, and sTNFR1. The drug also met all secondary endpoints related to safety and tolerability standards. Full study results are expected to be released in 2024.
The company has already submitted and received approval for three Investigational New Drug Applications for MyMD-1, which is now advancing in clinical programs for conditions like sarcopenia, rheumatoid arthritis, and Hashimoto's disease. With a unique oral dosing method, MyMD-1 offers a promising alternative to current TNF-α inhibitors, which typically require infusion or injection.
Partnerships and Future Outlook:
Through strategic partnerships and ongoing research, MyMD Pharmaceuticals aims to pioneer the development of therapies that not only manage symptoms but also extend the healthy lifespan of patients. With its robust pipeline and innovative approaches, MyMD Pharmaceuticals is well-positioned to make a significant impact in the field of autoimmune and age-related disease treatment.
For up-to-date news and developments, visit the StockTitan website.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced the issuance of U.S. Patent No. 11,085,047 for its drug candidate Supera-CBD, aimed at treating substance addiction and neurodegenerative diseases. Supera-CBD, a synthetic cannabidiol derivative, is projected to be significantly more effective than plant-derived CBD in treating conditions such as anxiety and chronic pain. The patent strengthens the company’s intellectual property position, adding to its existing 11 patents for the MYMD-1 drug platform, and supports the advancement towards human clinical trials.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced that its subsidiary, Oravax Medical, is set to initiate clinical trials for an oral COVID-19 vaccine, starting in Israel. This vaccine is designed for both standalone use and as a booster for previously vaccinated individuals. MyMD holds a 13% stake in Oravax and a 2.5% royalty on future net sales. The potential spin-off of Oravax could benefit MyMD shareholders, with Oravax's vaccine being a triple antigen candidate, possibly offering broader protection against mutations. A Phase 2 trial for MyMD's MYMD-1 is also anticipated by Q4 2021.
MyMD Pharmaceuticals (Nasdaq: MYMD) recently announced that its lead clinical compound, MYMD-1, has shown effectiveness in suppressing cytokine storms, a critical factor in COVID-19 severity. The drug inhibits TNF-α, potentially mitigating the immune system's overreaction that leads to severe outcomes. MYMD-1 is also being researched for COVID-19-related depression, with a Phase 2 trial in collaboration with a major medical school. The company aims to expedite MYMD-1's FDA approval through emergency programs, highlighting its dual focus on treating COVID-19 and extending healthy lifespan.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced data from a study by Eurofins Discovery that indicates commonality between its lead compound MYMD-1 and three FDA-approved JAK inhibitors for treating autoimmune diseases. The JAK inhibitor market is currently valued at $11 billion, projected to exceed $300 billion by 2026. MYMD-1 is also a selective TNF-α inhibitor and can cross the blood-brain barrier, providing additional advantages for patients with chronic inflammation. The FDA has issued warnings for existing JAK inhibitors, highlighting the potential safety advantages of MYMD-1.
MyMD Pharmaceuticals has announced promising data from a study on MYMD-1, its lead compound, conducted by Eurofins Discovery. The study shows MYMD-1's significant anti-proliferative effects compared to leading TNF inhibitors, indicating its potential to treat autoimmune and age-related diseases. MYMD-1 effectively regulates the immune system by selectively inhibiting TNF-alpha, a driver of chronic inflammation, without the adverse effects seen in current therapies. MyMD plans further studies as it progresses toward Phase 2 clinical trials.
MyMD Pharmaceuticals (Nasdaq: MYMD) has been approved for inclusion in the Russell Microcap® Index, effective post-market on June 28, 2021. This annual reconstitution enhances the company's visibility within the investment community and opens opportunities for new investors.
The Russell indexes are a significant benchmark, with over $10.6 trillion in assets linked to them, increasing MyMD's profile among institutional investors. The company aims to extend healthy lifespan through its clinical-stage drug platforms, MYMD-1 and Supera-CBD.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company, has announced the appointment of David Rini to its Scientific Advisory Board. Rini, a Professor at Johns Hopkins University with extensive experience in medical illustration, expressed his enthusiasm for collaborating on the company's therapeutic platforms. MyMD focuses on two platforms: MYMD-1, targeting autoimmune diseases and aging, and Supera-CBD, a novel synthetic CBD derivative aimed at the growing market. A presentation relevant to these developments is scheduled for May 17th at 4:15 PM ET.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced a conference call scheduled for May 17th at 4:15 p.m. ET to discuss its clinical and drug development plans. The call can be accessed via a registration link or by dialing in. The company is focused on two therapeutic platforms: MYMD-1, aimed at treating autoimmune diseases, and Supera-CBD, a synthetic derivative of CBD targeting key receptors. The press release includes a cautionary statement regarding forward-looking statements that highlight various risks associated with MyMD's pharmaceutical candidates.
MyMD Pharmaceuticals, a clinical stage pharmaceutical company (Nasdaq: MYMD), announced research findings on its compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The research from Johns Hopkins University highlights Supera-CBD's potential for treating psychiatric disorders by targeting the cannabinoid receptor type 2. Preliminary studies show Supera-CBD has strong anxiolytic effects and binds to CB2 with nearly four times the affinity of CBD. The presentation is scheduled for April 28, 2021, at 4:15 p.m. ET.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced that the USPTO has issued a Notice of Allowance for its patent application regarding Supera-CBD, a synthetic cannabinoid compound aimed at treating substance addiction and other disorders. This patent recognizes Supera-CBD's significant efficacy in inhibiting cannabinoid receptor type 2 (CB2), essential for managing neuroinflammatory and neurodegenerative diseases. The compound demonstrates 7-8x greater effectiveness than plant-derived CBD in specific therapeutic functions. MyMD is advancing plans for human clinical trials to evaluate Supera-CBD's potential in treating anxiety, chronic pain, and seizures.
FAQ
What is the current stock price of MyMD Pharmaceuticals (MYMD)?
What is the market cap of MyMD Pharmaceuticals (MYMD)?
What is MyMD Pharmaceuticals, Inc.?
What are the main therapeutic platforms developed by MyMD Pharmaceuticals?
What is MyMD-1?
What is Supera-CBD?
What recent achievements has MyMD Pharmaceuticals made?
What conditions is MyMD-1 being developed to treat?
How is MyMD-1 administered?
What are the potential benefits of Supera-CBD?
Has MyMD Pharmaceuticals received any regulatory approvals?
What is the future outlook for MyMD Pharmaceuticals?
